Liraglutide: A New Option for the Treatment of Obesity

Pharmacotherapy

Volumn 35, Issue 10, 2015, Pages 926-934

  Nuffer, Wesley A ^a   Trujillo, Jennifer M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

GLP 1; glucagon like peptide 1 receptor agonist; liraglutide; obesity; Saxenda; weight loss

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1;

ABDOMINAL PAIN; ARTICLE; COMORBIDITY; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; ELIMINATION HALF-LIFE; EXERCISE; FATIGUE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFECTION; LOW CALORY DIET; LOW FAT DIET; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; SATIETY; SIDE EFFECT; SLEEP DISORDERED BREATHING; STOMACH EMPTYING; THYROID CANCER; UPPER ABDOMINAL PAIN; VOLUME OF DISTRIBUTION; VOMITING; WEIGHT REDUCTION; AGONISTS; BODY WEIGHT; DRUG APPROVAL; DRUG EFFECTS; ECONOMICS; FOOD AND DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ANTI-OBESITY AGENTS; BODY WEIGHT; COMORBIDITY; DRUG APPROVAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIRAGLUTIDE; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEIGHT LOSS;

EID: 84945137054     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1639     Document Type: Article

References (33)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. J Am Med Assoc 2012; 307 (5): 483-90.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. J Am Med Assoc 2012; 307 (5): 491-7.
3. Ogden CL, Carroll MD, Kit BK, Flegal KM,. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311 (8): 806-14.
4. Centers for Disease Control and Prevention. Summary health statistics for U.S. adults: National Health Interview Survey, 2010. Hyattsville, MD: National Center for Health Statistics. Vital and Health Statistics 10(252); 2012.
5. National Heart, Lung, and Blood Institute Education Initiative. Expert panel on the identification, evaluation, and treatment of overweight and obesity in adults. Available from http://www.nhlbi.nih.gov/files/docs/guidelines/prctgd-c.pdf. Accessed May 27, 2015.
6. Finkelstein EA, Trogdon JG, Cohen JW, et al., Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff 2009; 28 (5): w822-31.
7. Apovian CM, Aronne LJ, Bessesen DH, et al., Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100 (2): 342-62.
8. Jensen MD, Ryan DH, Apovian CM, et al., 2013 AHA/ACC/TOS guidelines for the management of overweight and obesity in adults. J Am Coll Cardiol 2014; 63 (25-PA): 2985-3023.
9. Obesity Society. Expert Panel Report: guidelines (2013) for the management of overweight and obesity in adults. Obesity 2014; 22: S41-410.
10. Canadian Task Force on Preventive Health Care. Recommendations for prevention of weight gain and use of behavioral and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ 2015; 187 (3): 184-95. doi: 10.1503/cmaj.140887.
11. Pasanisi F, Contaldo F, de Simone G, Mancini M,. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis 2001; 11 (6): 401-6.
12. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M,. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
13. Degn KB, Juhl CB, Sturis J, et al., One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-94.
14. Marre M, Shaw J, Brandle M, et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-78.
15. Nauck M, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32: 184-90.
16. Garber A, Henry R, Ratner R, et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-81.
17. Zinman B, Gerich J, Buse J, et al., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-30.
18. Russell-Jones D, Vaag A, Schmitz O, et al., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-55.
19. Turton MD, O'Shea D, Gunn I, et al., A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
20. Tang-Christensen M, Larsen PJ, Goke R, et al., Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-56.
21. Hansen L, Deacon CF, Orskov C, Holst JJ,. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-63.
22. Tong J, D'Alessio D,. Giving the receptor a brake: slowing gastric emptying by GLP-1. Diabetes 2014; 63: 407-9.
23. Bode B,. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract 2012; 97: 27-42.
24. Meece J,. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Pharmacotherapy 2009; 29 (12 pt 2): 33S-42S.
25. SAXENDA (liraglutide) [package insert]. Plainsboro, NJ; Novo Nordisk; Published January, 2015. Available from http://www.novo-pi.com/saxenda.pdf. Accessed May 27, 2015.
26. Astrup A, Rossner S, Van Gaal L, et al., Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374 (9701): 1606-16.
27. Pi-Sunyer X, Astrup A, Fujioka K, et al., A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
28. Davies M, Bergenstal R, Bode B, et al., Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314 (7): 687-699.
29. Wadden T, Hollander P, Klein S, et al., Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes 2013; 37: 1443-51.
30. Liraglutide 3970. Effect of liraglutide in obese subjects with moderate or severe obstructive sleep apnoea: SCALE-Sleep Apnoea. 2015. Clinical Trials.gov identifier NCT01557166. Available from https://www.clinicaltrials.gov/ct2/show/NCT01557166?term=Liraglutide+3970&rank=1. Accessed May 27, 2015.
31. Red Book Online, Micromedex 2.0. Ann Arbor, MI: Truven Health Analytics. Accessed May 27, 2015.
32. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A,. Second phase of a double-blind study clinical trial on sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes Relat Metab Disord 2001; 25: 741-7.
33. Sjostrom L, Rissanen A, Andersen T, et al., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-72.